Scarica l'app Stockscreener
8.19
8.08%
-0.72
Candel Therapeutics Inc Borsa (CADL) Ultime notizie
Form 4 Candel Therapeutics Inc: Paul B. Manning (Director) For: 30 September - Investing.com
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance Australia
A director receives 2,189 options instead of quarterly cash pay at Candel Therapeutics (CADL). - Stock Titan
Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewswire Inc.
Form 4 Candel Therapeutics Inc For: 2 October By Investing.com - Investing.com Nigeria
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo! Finance Canada
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Candel Therapeutics: Strong Buy On Aglatimagene Prostate Cancer BLA Filing In Q4 (CADL) - Seeking Alpha
Candel Therapeutics Insider Sold Shares Worth $3,160,783, According to a Recent SEC Filing - Yahoo Finance
CADL Slides As Form 144 Filing Flags Insider Selling Risk - timothysykes.com
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com Australia
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com South Africa
Candel Therapeutics CEO Tak sells $3.16m in CADL stock By Investing.com - Investing.com India
Candel Therapeutics (NASDAQ: CADL) CEO sells 280K shares under preset plan - Stock Titan
Candel Therapeutics CEO Tak sells $3.16m in CADL stock - Investing.com
Candel Therapeutics (NASDAQ: CADL) investor plans $3.4M Rule 144 stock sale from equity awards - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com India
Candel (CADL) gives director options with 36-month vesting - Stock Titan
Candel Therapeutics at Cantor global healthcare conference: prostate cancer push - Investing.com Canada
Candel Therapeutics, Inc. Announces Appointment of Martine Zimmermann to Board of Directors, Effective September 8, 2026 - marketscreener.com
Candel Therapeutics Adds Regulatory Veteran to Board Ahead of Q4 2026 BLA Submission - Minichart
Candel Therapeutics Adds Martine Zimmermann to Board Ahead of Planned BLA Filing - citybiz
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Canada
Candel Therapeutics appoints Martine Zimmermann to board - investing.com
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - The Manila Times
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com UK
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors - Yahoo Finance
Candel Therapeutics appoints Martine Zimmermann to board By Investing.com - Investing.com Nigeria
Candel Therapeutics Expands Board with Appointment of Martine Zimmermann, Pharm.D. - Kalkine Media
BB: BlackBerry Ltd Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
(CADL) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Candel Therapeutics Stock Price Forecast. Should You Buy CADL? - StockInvest.us
CADL 8-K FilingsCandel Therapeutics, Inc. SEC 8-K - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Show Me The Money: CADL Delivers 190%+ Gain In Less Than Six Months As BLA Filing Nears - RTTNews
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com South Africa
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com Canada
Candel Therapeutics stock hits 52-week high at $13.96 - investing.com
Candel Therapeutics stock hits 52-week high at $13.96 By Investing.com - Investing.com UK
Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight - PR Newswire UK
Candel Therapeutics to Present at September Investor Conferences - The Manila Times
Candel Therapeutics (CADL) Is Up 5.4% After Steep Q2 Loss Widening Has The Bull Case Changed? - Yahoo Finance
Analysts Issue Forecasts for CADL FY2026 Earnings - MarketBeat
Candel Therapeutics, Inc. (CADL) Stock Price, News, Quote & History - Yahoo Finance
Candel Therapeutics (CADL) Faces Bigger Losses As Its Valuation Still Looks Pricey - Yahoo Finance
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (CADL) Is Up 26.4% After Swinging Back to Losses in Q2 2026 – Has The Bull Case Changed? - simplywall.st
Candel Therapeutics (NASDAQ:CADL) CTO Seshu Tyagarajan Sells 7,000 Shares of Stock - MarketBeat
3.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):